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Abstract: We conducted a systematic review for evidence of the clinical efficacy of cancer
immunotherapies. We searched PubMed from inception to 14 February 2018 for meta-analyses of
randomized controlled trials (RCTs) of cancer immunotherapies. Re-analyses were performed to
estimate the summary effect size under random-effects, the 95% confidence interval (CI), heterogeneity,
and the 95% prediction interval, and we determined the strength of the evidence. We examined
publication bias and excess significance bias. 63 articles corresponding to 247 meta-analyses were
eligible. Nine meta-analyses were classified to have convincing evidence, and 75 were classified as
suggestive evidence. The clinical benefit of immunotherapy was supported by convincing evidence
in the following settings: anti-PD-1/PD-L1 monoclonal antibody (mAb) therapy for treating advanced
melanoma and non-small cell lung cancer (NSCLC), the combination of rituximab and chemotherapy
for treating chronic lymphocytic leukemia and B-cell non-Hodgkin’s lymphoma, adoptive cell
immunotherapy for NSCLC, and the combination of interferon α and chemotherapy for metastatic
melanoma. A further meta-analysis of 16 RCTs showed that anti-PD-1/PD-L1 mAb therapy had
a benefit in patients with solid tumors (overall survival; hazard ratio = 0.73, 95% CI: 0.68–0.79;
p < 0.001), supported by convincing evidence. In the future, rigorous approaches are needed when
interpreting meta-analyses to gain better insight into the true efficacy of cancer immunotherapy.
Keywords: immunotherapy; cancer; umbrella review; meta-analysis
1. Introduction
Cancer immunotherapy was first introduced in the late 19th century. Dr. William Coley, after
observing cases in which a patient’s sarcoma regressed after being infected withStreptococcus pyogenes [1],
administered a mixture of inactivated S. pyogenes and Serratia marcescens known as “Coley’s toxins”
to patients with various carcinomas, which resulted in activation of the immune system against the
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tumor cells [2]. For the last three decades, progress in our understanding of the immune system, cancer
etiology, oncogenes, tumor microenvironment, and advances in molecular biology has opened up a
new paradigm of cancer immunotherapy and targeted treatments [2,3].
The principal goal of cancer immunotherapy is to enhance the patient’s existing immune response
to launch a sustained attack on cancer cells [2,3]. Anti-CD20 monoclonal antibodies (mAbs) bind to
CD20 expressed by neoplastic B cells which results in their lysis [3]. Programmed cell death protein 1
(PD-1)/Programmed cell death protein ligand 1 (PD-L1) mAbs abrogate the inhibitory interaction
between PD-L1 expressed by tumor cells and immunosuppressive cells in the tumor microenvironment
and PD-1 expressed by effector T-cells, thereby enhancing the effector T-cell’s antineoplastic activity [4].
Adoptive cell transfer immunotherapy involves (1) collection of tumor-infiltrating lymphocytes or
circulating lymphocytes, (2) their culture/selection/modification/expansion ex vivo, (3) and their
(re-)administration to patients [3]. For example, cytokine-induced killer cells (CIK) are mononuclear
cells incubated with various cytokines [5], and are sometimes co-cultured with dendritic cells (DCs)
to enhance cytocidal effects [6]. Cytokines such as interferon alpha (IFN-α) and interleukin 2 (IL-2)
are administered to cancer patients as an immunomodulatory agent to promote various anticancer
activities. Tumor antigen vaccines such as DC-based vaccine Sipuleucel-T is applied to promote
tumor-specific immune responses [6,7].
Numerous efforts have been made to assess the clinical efficacy of a diverse range of cancer
immunotherapies. However, to the best of our knowledge, there has been no effort to summarize and
examine the statistical validity of these immunotherapeutic approaches in terms of their potential
limitations such as the presence of various biases. For this reason, we performed an umbrella review
of all available meta-analyses of randomized controlled trials (RCTs) reporting on the efficacy of
cancer immunotherapy to provide an insight into which cancer immunotherapy is truly an effective
therapeutic approach.
2. Results
A total of 424 articles from a pre-defined PubMed search were screened (Figure S1), and 63
articles were considered eligible, corresponding to 222 original meta-analyses, which were conducted
only on RCTs. The eligible meta-analyses also reported 25 original meta-analyses containing
non-RCT(s), and re-analysis on only RCTs were reported as the primary outcome. Re-analyses
of 247 original meta-analyses corresponding to 1,306 individual study outcomes (excluding non-RCTs)
and 324,856 patient data were reported as the primary outcome. It is worth noting that, because
there were often several meta-analyses studying a similar topic performed independently by different
groups, there were some overlapping RCTs among the meta-analyses of a similar topic. We did not
track and count all the RCTs excluding the overlapping ones included in every meta-analysis (with the
exception of PD-1/PD-L1 inhibitor OS, PD-1/PD-L1 inhibitor PFS, and DC/CIK OS, as described below),
as this was beyond the scope of our umbrella review. Rather, we focused on performing the re-analysis
of eligible meta-analyses to verify the statistical validity of each meta-analysis.
The types of immunotherapy were classifiable into five main categories: (1) a mAb group,
which included anti-PD-1/PD-L1 mAb and rituximab (15 articles studying the treatment), (2) an adoptive
cell immunotherapy group, which included DC/CIK and CIK (15 articles), (3) an immunomodulatory
cytokine group, which included IFN-α and IL-2 (25 articles), (4) a vaccine group, which included the
DC vaccine Sipuleucel-T (9 articles), and (5) another immunotherapy group in which the types of
immunotherapy were inconsistent or not specified in the original study (7 articles). The median number
of studies per meta-analysis was 4 (interquartile range (IQR) 3–7), and the median number of total
participants per meta-analysis was 885 (IQR 410–1,542). Under the random-effects model, 71 (29%) of the
meta-analyses were statistically significant with a p < 0.001, while 75 (30%) were statistically significant,
with 0.001 < p < 0.05. Only 9 (4%) outcomes were determined to have convincing evidence of cancer
immunotherapy (6 in the mAb group, 1 in the adoptive cell immunotherapy group, and 2 in the cytokine
group) as an effective therapeutic agent compared to the control intervention. Seventy-five (30%)
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outcomes showed suggestive evidence, 58 (23%) showed weak evidence in favor of immunotherapy,
4 (2%) showed weak evidence in favor of control therapy, and 101 (41%) were not statistically significant.
More detailed descriptive statistics according to immunotherapy groups is shown in Table S1 of the
Supplementary Materials. Major results of the re-analysis are presented in Tables 1–3, and statistically
significant results among them are shown in Figures S2–S4 of the Supplementary Materials. All results
of the re-analysis are presented in Tables S2–S7 of the Supplementary Materials.
2.1. Monoclonal Antibodies
Articles of meta-analyses of anti-PD-1/PD-L1 mAb therapy have been published since 2016,
reaching six until 2017 (Tables 1 and S2, Figure S2). Anti-PD-1/PD-L1 mAbs showed a benefit
over chemotherapy in improving progression-free survival (PFS) and the overall response rate
(ORR) of advanced melanoma patients with a relatively large effect size, supported by convincing
evidence. The anti-PD-l mAb nivolumab improved PFS of melanoma patients compared to ipilimumab.
Anti-PD-1/PD-L1 mAbs also showed benefit over chemotherapy in overall survival (OS) and PFS of
patients with non-small cell lung cancer (NSCLC), supported by convincing evidence and suggestive
evidence, respectively. Wang et al. incorporated data from 10 available trials studying anti-PD-1/PD-L1
mAb therapy in patients with melanoma, NSCLC, and renal cell cancer (RCC) [8]. The study showed
that anti-PD-1/PD-L1 mAb therapy was effective at improving PFS, OS, ORR, and stable disease
rate in patients with solid cancers with a relatively large study effect, although high in-between
heterogeneity existed.
Concerning the efficacy of anti-PD-1/PD-L1 mAb therapy, no study sufficiently contained all
available RCTs of interest in one meta-analysis, so we performed new meta-analyses with all eligible
RCTs that we found (Figures S5 and S6), including RCTs from the most recent meta-analysis available [9].
Our meta-analysis of 16 RCTs (8,263 patients) of anti-PD-1/PD-L1 mAbs (9 studies with nivolumab,
5 with pembrolizumab, and 2 with atezolizumab) regarding the OS of patients with gastric or
gastro-esophageal junction cancer (2 studies), head-and-neck squamous cell carcinoma (1 study),
melanoma (4 studies), NSCLC (7 studies), RCC (1 study), and urothelial cancer (1 study) demonstrated
a beneficial effect of anti-PD-1/PD-L1 mAbs over conventional therapies (hazard ratio (HR) = 0.73, 95%
confidence interval (CI): 0.68 to 0.79; p < 0.001), supported by convincing evidence, despite moderate
heterogeneity (I2 = 39%). Meta-analysis of 18 trials (9,748 patients) regarding an effect on PFS of
anti-PD-1/PD-L1 mAbs (10 trials with nivolumab, 6 with pembrolizumab, and 2 with atezolizumab) in
patients with gastric or gastro-esophageal junction cancer (2 studies), head-and-neck squamous cell
carcinoma (1 study), melanoma (6 studies), NSCLC (7 studies), RCC (1 study), and urothelial cancer
(1 study) showed improved PFS (HR = 0.73, 95% CI 0.65 to 0.84; p < 0.001). However, unlike the analysis
of OS, the meta-analysis of PFS showed high heterogeneity (I2 = 87%) and 95% prediction interval (PI),
which included the null. Reasons for the high heterogeneity could have been due to the difference in
cancer type and the difference in medication. Differences in patient characteristics such as sex or PD-L1
expression level may have also accounted for the high in-between study heterogeneity [9,10].
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Table 1. Main findings and level of evidence reported in meta-analyses of cancer therapeutic anti-PD-1/PD-L1 and anti-CD20 monoclonal antibodies.
Author,
Year Comparison Cancer Type
RCT
n.
Intervention
/Control Outcome Metrics R/N/S †
R
p-Value
R SE
(95% CI) I2(%)
95%
Prediction
interval
Egger
p-Value
Excess
Significance
Level of
Evidence
Anti-PD-1/PD-L1 mAb
Guan et al.
2016 Anti-PD-1/PD-L1 vs CTx Advanced melanoma 3 843/699 PFS HR 0/1/3 <0.001
0.50
(0.43–0.59) 18 0.32–0.80 0.24 p > 0.1 Convincing
Guan et al.
2016 Anti-PD-1/PD-L1 vs CTx Advanced melanoma 3 843/699
Overall
response RR 0/0/4 <0.001
3.23
(2.37–4.41) 0 1.64–6.39 0.19 p > 0.1 Convincing
Hao et al.
2017 Nivolumab vs ipilimumab
Metastatic advanced
melanoma 2 871/593 PFS HR 0/0/2 <0.001
0.58
(0.48–0.69) 0 - - p > 0.1 Weak
Hao et al.
2017
Nivolumab + ipilimumab vs
ipilimumab
Metastatic advanced
melanoma 2 410/362 PFS HR 0/0/2 <0.001
0.40
(0.31–0.52) 0 - - NA Weak
Hao et al.
2017
Nivolumab or pembrolizumab vs
CTx
Metastatic advanced
melanoma 3 843/520 PFS HR 0/1/2 <0.001
0.43
(0.37–0.50) 0 0.16–1.14 0.09 NA Weak
Wang et al.
2017 Anti-PD-1/PD-L1 vs CT Melanoma 6 1198/974
Objective
response RR 0/0/6 <0.001
2.89
(2.03–4.11) 70 0.98–8.52 0.51 p > 0.1 Suggestive
Yun et al.
2016
Anti-PD-1 or Anti-CTLA-4 vs CTx
or VAX
Metastatic, unresectable,
cutaneous melanoma 4 1328/923 OS RR 0/0/4 0.001
0.72
(0.60–0.88) 83 0.30–1.75 0.25 p > 0.1 Suggestive
Yun et al.
2016
Anti-PD-1 or Anti-CTLA-4 vs CTx
or VAX
Metastatic, unresectable,
cutaneous melanoma 6 1961/1235 PFS RR 0/2/4 <0.001
0.84
(0.77–0.92) 84 0.61–1.16 0.17 p > 0.1 Suggestive
Zhuansun
et al. 2017 Anti-PD-1/PD-L1 vs CTx
Pretreated advanced
NSCLC 4 1261/913 OS HR 0/1/3 <0.001
0.68
(0.61–0.75) 0 0.53–0.86 0.99 p > 0.1 Convincing
Zhuansun
et al. 2017 Anti-PD-1/PD-L1 vs CTx
Pretreated advanced
NSCLC 4 1261/913 PFS HR 0/2/2 0.009
0.81
(0.70–0.95) 57 0.45–1.49 0.89 p > 0.1 Suggestive
Wang et al.
2017 Anti-PD-1/PD-L1 vs CT
Melanoma or NSCLC or
RCC 10 3105/2141 PFS HR 0/4/6 <0.001
0.65
(0.53–0.79) 81 0.33–1.26 0.23 p > 0.1 Suggestive
Wang et al.
2017 Anti-PD-1/PD-L1 vs CT
Melanoma or NSCLC or
RCC 9 2035/1812
Objective
response RR 0/0/9 <0.001
2.92
(2.07–4.12) 80 0.93–9.19 0.55 p > 0.1 Suggestive
Wang et al.
2017 Anti-PD-1/PD-L1 vs CT
Melanoma or NSCLC or
RCC 9 2035/1812
Stable
disease rate RR 0/4/5 <0.001
0.58
(0.45–0.75) 81 0.24–1.36 0.59 p > 0.1 Suggestive
Anti-PD-1/
PD-L1 solid
tumor OS||
Anti-PD-1/PD-L1 vs CT
Gastric or
gastro-esophageal junction
cancer or head-and-neck
squamous cell carcinoma
or melanoma or NSCLC or
RCC or urothelial cancer
16 4681/3582 OS HR 0/3/13 <0.001 0.73(0.68–0.79) 39 0.59–0.92 0.72 p > 0.1 Convincing
Anti-PD-1/
PD-L1 solid
tumor PFS||
Anti-PD-1/PD-L1 vs CT
Gastric or
gastro-oesophageal
junction cancer or
head-and-neck squamous
cell carcinoma or
melanoma or NSCLC or
RCC or urothelial cancer
18 5672/4076 PFS HR 0/9/10 <0.001 0.73(0.65–0.84) 87 0.41–1.30 0.25 p > 0.1 Suggestive
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Table 1. Cont.
Author,
Year Comparison Cancer Type
RCT
n.
Intervention
/Control Outcome Metrics R/N/S †
R
p-Value
R SE
(95% CI) I2(%)
95%
Prediction
interval
Egger
p-Value
Excess
Significance
Level of
Evidence
Anti-CD20 mAb
Bauer et al.
2012 Rituximab + CTx vs CTx
Chronic lymphocytic
leukemia 3 710/711 PFS HR 0/1/2 <0.001
0.65
(0.52–0.83) 50 0.06–7.00 0.75 p > 0.1 Suggestive
Bauer et al.
2012 Rituximab + CTx vs CTx
Chronic lymphocytic
leukemia 3 710/711
Overall
response RR 0/1/2 <0.001
1.14
(1.08–1.20) 0 0.81–1.61 0.63 p > 0.1 Suggestive
Nunes et al.
2015 Rituximab + CTx vs CTx
Chronic lymphocytic
leukemia 4 1231/1202
Complete
remission OR 0/1/3 <0.001
2.59
(2.14–3.14) 0 1.70–3.96 0.13 p > 0.1 Convincing
Gao et al.
2010 Rituximab + CTx vs CTx
B-cell non-Hodgkin’s
lymphoma 11 2486/2447 OS RR 0/6/5 <0.001
1.08
(1.05–1.11) 20 1.02–1.14 0.28 p > 0.1 Convincing
Gao et al.
2010 Rituximab + CTx vs CTx
B-cell non-Hodgkin’s
lymphoma 11 2470/2333 DCR RR 0/4/7 <0.001
1.36
(1.26–1.46) 51 1.11–1.67 0.21 p > 0.1 Convincing
Hou et al.
2011 Rituximab + CTx vs CTx
B-cell non-Hodgkin’s
lymphoma 7 178/179
Complete
response OR 0/5/2 <0.001
2.99
(1.90–4.71) 0 1.65–5.43 0.54 p > 0.1 Suggestive
Schulz et al.
2007 Rituximab + CTx vs CTx
Indolent or mantle cell
lymphoma 7 994/949 OS HR 0/4/3 0.001
0.70
(0.57–0.87) 19 0.46–1.08 0.82 p > 0.1 Suggestive
Schulz et al.
2007 Rituximab + CTx vs CTx
Indolent or mantle cell
lymphoma 7 978/935 DCR HR 0/1/6 <0.001
0.70
(0.59–0.84) 72 0.40–1.24 0.51 p > 0.1 Suggestive
Vidal et al.
2017
Rituximab maintenance vs obs or
treatment only at relapse Follicular lymphoma 9 1145/1170 OS HR 0/8/1 0.007
0.79
(0.66–0.94) 0 0.64–0.97 0.91 p > 0.1 Suggestive
Zhou et al.
2017 Rituximab maintenance vs obs
Diffuse large B-Cell
lymphoma 3 658/661 PFS HR 0/1/2 0.017
0.71
(0.54–0.94) 43 0.05–10.68 0.67 p > 0.1 Suggestive
Zhou et al.
2017 Rituximab maintenance vs obs
Diffuse large B-Cell
lymphoma 4 735/686
Event-free
survival HR 0/3/1 0.004
0.80
(0.69–0.93) 0 0.58–1.11 0.78 p > 0.1 Suggestive
Abbreviations: RCT, randomized controlled trial; n., number; SE, standard effect; CI, confidence interval; M, model; F, fixed effect; R, random effect; NA, not available; C, concordance with
largest study; Y, concordant with largest study; N, not concordant with largest study; OS, overall survival; PFS progression-free survival; RR, risk ratio; HR, hazard ratio; OR, odds ratio;
CTx, chemotherapy; CT, conventional therapy; VAX, vaccine; obs; NSCLC, non-small cell lung cancer; RCC, renal cell cancer. † Number of individual studies of effect size with statistically
significant direction in favor of control therapy/not statistically significant/statistically significant in favor of immunotherapy. ||Re-analysis was performed on all eligible RCTs we found.
References are provided in the Reference Appendix of the Supplementary Materials. All p-values are two-sided.
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Table 2. Main findings and level of evidence reported in meta-analyses of adoptive cell immunotherapy for cancer.
Author,
Year Comparison Cancer Type
RCT
n.
Intervention
/Control Outcome Metrics R/N/S †
R
p-Value
R SE
(95% CI) I
2(%)
95%
Prediction
Interval
Egger
p-Value
Excess
Significance
Level of
Evidence
Dendritic cells with cytokine-induced killer cells
Su et al.
2016 DC/CIK vs obs with backbone TACE HCC 5 250/245 DCR OR 0/3/2 0.033
1.84
(1.05–3.24) 18 0.35–9.60 0.55 p > 0.1 Suggestive
Su et al.
2016 DC/CIK vs obs with backbone TACE HCC 3 104/106 1-year OS OR 0/3/0 0.027
2.00
(1.08–3.70) 0 0.04–107.12 0.12 p > 0.1 Weak
Wang et al.
2015 DC/CIK + CT vs CT NSCLC 5 191/192 PFS HR 0/2/3 <0.001
0.53
(0.39–0.71) 0 0.32–0.86 0.76 p > 0.1 Suggestive
Zheng et al.
2015 DC/CIK + CTx vs CTx NSCLC 3 141/141 DCR RR 0/1/2 0.007
1.26
(1.07–1.50) 10 0.36–4.47 0.22 p > 0.1 Suggestive
DC/CIK
NSCLC OS|| DC/CIK + CT vs CT NSCLC 10 387/427
Longest OS
reported RR 0/7/3 <0.001
0.82
(0.75–0.89) 0 0.74–0.90 0.19 p > 0.1 Suggestive
Lan et al.
2015 DC/CIK + CTx vs CTx
Solid tumor, NSCLC or rectal cancer
or colorectal cancer or colon cancer
or breast cancer or gastric cancer
5 195/202 3-year OS OR 0/4/1 0.007 0.37(0.18–0.77) 35 0.06–2.51 0.28 p > 0.1 Suggestive
Lan et al.
2015 DC/CIK + CTx vs CTx
Solid tumor, NSCLC or rectal cancer
or colorectal cancer or colon cancer
or breast cancer or gastric cancer
6 207/224 Overallresponse OR 0/5/1 0.005
0.54
(0.35–0.83) 0 0.30–0.99 0.36 p > 0.1 Suggestive
Cytokine-induced killer cells
Li et al.
2016 Adjuvant CIK vs no AT
Treated HCC, Barcelona-clinic liver
cancer B or earlier stage 7 460/405 PFS RR 0/5/2 0.004
0.76
(0.63–0.91) 66 0.45–1.29 0.02 p > 0.1 Weak
Li et al.
2016 Adjuvant CIK vs no AT
Treated HCC, Barcelona-clinic liver
cancer B or earlier stage 5 380/335 OS RR 0/3/2 0.021
0.78
(0.64–0.96) 42 0.44–1.39 0.04 p > 0.1 Weak
Wang et al.
2016 CIK vs no AT after resection Resected HCC 5 402/357 3-year OS RR 0/5/0 0.010
1.15
(1.03–1.28) 0 0.97–1.36 0.91 p > 0.1 Weak
Wang et al.
2016 CIK vs no AT after resection Resected HCC 5 402/357
3-year
recurrence-free
survival
RR 0/4/1 0.007 1.33(1.08–1.64) 7 0.90–1.98 0.87 p > 0.1 Suggestive
Yu et al.
2017 Adjuvant CIK + CT vs CT HCC 7 451/422 OS HR 0/3/4 <0.001
0.64
(0.51–0.82) 50 0.34–1.23 0.25 p > 0.1 Suggestive
Other adoptive cellular immunotherapies
Yuan et al.
2017
Postoperative ACI (CIK or LAK + IL-2
or lymphocytes) vs no AT Pretreated HCC, not advanced 6 407/362
3-year
mortality RR 0/5/1 0.009
0.71
(0.55–0.92) 0 0.49–1.02 0.81 p > 0.1 Suggestive
Yuan et al.
2017
Postoperative ACI (CIK or LAK + IL-2
or lymphocytes) vs no AT Pretreated HCC, not advanced 6 407/362
3-year
recurrence
rate
RR 0/5/1 0.001 0.81(0.72–0.92) 0 0.68–0.97 0.30 p > 0.1 Suggestive
Zeng et al.
2016
Postoperative ACI (AKT-DC or
DC/CIK or LAK + IL-2 or TIL + rIL-2)
+ CT vs CT
Resected NSCLC 4 234/238 OS HR 0/3/1 0.013 0.59(0.39–0.89) 40 0.14–2.56 0.16 p > 0.1 Suggestive
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Table 2. Cont.
Author,
Year Comparison Cancer Type
RCT
n.
Intervention
/Control Outcome Metrics R/N/S †
R
p-Value
R SE
(95% CI) I
2(%)
95%
Prediction
Interval
Egger
p-Value
Excess
Significance
Level of
Evidence
Other adoptive cellular immunotherapies
Zhao et al.
2017
ACI (LAK + IL-2 or DC/CIK or CIK or
AKT or TIL) vs CT NSCLC, operated or non-operated 11 669/755 2-year OS RR 0/5/6 <0.001
1.43
(1.30–1.58) 0 1.28–1.61 0.24 p > 0.1 Convincing
Zhao et al.
2017
ACI (LAK + IL-2 or DC/CIK or CIK or
AKT or TIL) vs CT NSCLC, operated or non-operated 8 529/613 3-year OS RR 0/5/3 <0.001
1.45
(1.24–1.69) 0 1.19–1.76 0.31 p > 0.1 Suggestive
Zhao et al.
2017
ACI (LAK + IL-2 or DC/CIK or CIK or
AKT or TIL) vs CT NSCLC, operated or non-operated 4 187/229 1-year PFS RR 0/2/2 0.031
1.46
(1.24–1.72) 0 1.02–2.09 0.16 p > 0.1 Suggestive
Tang et al.
2013
ACI (autolymphocyte or LAK or CIK)
vs no ACI Metastatic RCC 4 235/224 1-year OS RR 0/3/1 <0.001
1.33
(1.15–1.54) 0 0.97–1.83 0.205 p > 0.1 Suggestive
Abbreviations: RCT, randomized controlled trial; n., number; SE, standard effect; CI, confidence interval; M, model; F, fixed effect; R, random effect; NA, not available; C, concordance with
largest study; Y, concordant with largest study; N, not concordant with largest study; OS, overall survival; PFS progression-free survival; RR, risk ratio; HR, hazard ratio; OR, odds ratio;
TACE, Transcatheter arterial chemoembolization; CT, conventional therapy; CTx, chemotherapy; AT, adjuvant therapy; ACI, adoptive cell immunotherapy; CIK, cytokine-induced killer
cells; LAK, lymphokine-activated killer cells; IL-2, Interleukin-2; DC/CIK, dendritic cells with cytokine-induced killer cells; AKT, activated killer T-cells; TIL, tumor-infiltrating lymphocytes;
HCC, hepatocellular carcinoma; NSCLC, non-small cell lung cancer; RCC, renal cell cancer. † Number of individual studies of effect size with statistically significant direction in favor of
control therapy/not statistically significant/statistically significant in favor of immunotherapy. ||Re-analysis was performed on RCTs from all eligible meta-analyses we found. References
are provided in the Reference Appendix of the Supplementary Materials. All p-Values are two-sided.
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Nine studies corresponding to 28 meta-analyses assessed the efficacy of anti-CD20 mAb therapy,
all of which were performed with rituximab (Tables 1 and S3, Figure S2). The combination of rituximab
and chemotherapy showed a higher response rate and a better PFS compared to chemotherapy alone
in the management of chronic lymphocytic leukemia, supported by suggestive evidence, and an
improved complete remission rate, supported by convincing evidence. Three studies assessed the
induction therapy of non-Hodgkin’s lymphoma. Gao et al. is an updated study of Schulz et al. and
contains all its component studies, while Schulz et al. performed subgroup analyses of trials according
to lymphoma types [11,12]. Re-analysis of the study of Gao et al. showed that the combination of
rituximab and chemotherapy was more effective than chemotherapy alone when considering the
improvement in OS and disease control rate (DCR) of B-cell non-Hodgkin’s lymphoma, supported
by convincing evidence. In 2011, Hou et al. analyzed trials held in China that did not overlap with
the studies analyzed by Gao et al. [13]. Re-analysis of Hou et al. demonstrated the benefit of the
combination of rituximab and chemotherapy compared to chemotherapy alone on improving the
complete response rate of patients with B-cell non-Hodgkin’s lymphoma. Rituximab maintenance
therapy showed an improvement in event-free survival and PFS in patients with diffuse large B-cell
lymphoma and showed an improvement in OS of patients with follicular lymphoma.
2.2. Adoptive Cell Immunotherapy
The efficacy of adjuvant DC/CIK in treating patients with hepatocellular carcinoma (HCC) after
transcatheter arterial chemoembolization (TACE) treatment was shown by the improvement in DCR
and 1-year OS (Tables 2 and S4, Figure S3). In patients with NSCLC, the addition of DC/CIK to standard
therapy improved PFS and DCR. Additionally, we performed a meta-analysis of all available RCTs
studying the effect of DC/CIK on OS in patients with NSCLC (risk ratio (RR) = 0.82, 95% CI 0.75 to 0.89;
p < 0.001), which was classified as suggestive evidence because the total number of participants did not
exceed 1,000 subjects (Figure S7). The meta-analysis on trials of DC/CIK for various solid cancers was
classified as suggestive evidence for the improvement of OS and the objective response rate but was
based on a relatively small number of participants (<500) and lacked individual trials addressing each
type of cancer. Meta-analyses dealing with the efficacy of adjuvant CIK were performed on trials of
HCC patients and showed benefit on OS and recurrence-free survival. In all meta-analyses of DC/CIK
or CIK, 95% PI included the null, and the number of total participants was less than 1000.
In seven of 18 articles dealing with adoptive cell immunotherapy, meta-analyses were conducted
regardless of the type, such as DC/CIK, CIK, and tumor-infiltrating lymphocytes (Figure S3). Adjuvant
adoptive cell immunotherapy showed benefit on the 3-year recurrence rate and 3-year mortality
rate of HCC. The benefit of adoptive cell immunotherapy compared to control therapy on 2-year
OS of patients with NSCLC was supported by convincing evidence. The addition of postoperative
adoptive cell immunotherapy to conventional therapy for treating patients with resected NSCLC
resulted in an improvement of OS. adoptive cell immunotherapy treatment for RCC showed a benefit
on 1-year OS, supported by suggestive evidence, but this was based on a relatively small number of
participants (<500).
2.3. Immunomodulatory Cytokines
The clinical efficacy of immunomodulatory cytokines, mostly IFN- α and IL-2, was studied for
various cancers types (Tables 3 and S5, Figure S4). The addition of IFN-α to 5-fluorouracil therapy for
colorectal cancer did not show a clinical benefit. IFN-α maintenance therapy showed a clinical benefit
on PFS in patients with follicular lymphoma and on the OS of patients with NSCLC. Adjuvant therapy
with IFN-α resulted in an improvement in survival after surgical resection or TACE treatment of HCC
and showed a decrease in tumor recurrence rate.
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Table 3. Main findings and level of evidence reported in meta-analyses of cancer therapeutic immunomodulatory cytokines and cancer vaccines.
Author, Year Comparison Cancer Type RCTn.
Intervention
/Control Outcome Metrics R/N/S †
R
p-Value
R SE
(95% CI) I
2(%)
95%
Prediction
Interval
Egger
p-Value
Excess
Significance
Level of
Evidence
Interferon-α
Thirion, et al.
2000 IFN-α + 5FU vs leucovorin + 5FU Colorectal cancer 7 744/744 OS HR 0/7/0 0.403
1.02
(0.98–1.05) 0 0.96–1.08 0.38 p > 0.1
No
association
Thirion, et al.
2000
IFN-α + 5FU vs 5FU, with or without
leucovorin in both arms Colorectal cancer 12 879/887 OS HR 0/12/0 0.203
1.02
(0.99–1.05) 0 0.99–1.06 0.97 p > 0.1
No
association
Jiang, et al.
2013
Post-surgical adjuvant IFN (mostly IFN-α) vs
p after surgical resection or TACE
Pretreated HCC, viral
hepatitis related 9 498/451 Mortality OR 0/6/3 <0.001
0.43
(0.32–0.56) 0 0.31–0.59 0.91 p > 0.1 Suggestive
Jiang, et al.
2013
Post-surgical adjuvant IFN (mostly IFN-α) vs
p after surgical resection or TACE
Pretreated HCC, viral
hepatitis related 9 499/476 Recurrence rate OR 0/8/1 0.003
0.66
(0.51–0.87) 0 0.48–0.92 0.08 p > 0.1 Weak
Ives, et al.
2007 IFN-α + CTx vs CTx Metastatic melanoma 11 683/607
Overall
response OR 0/8/3 <0.001
0.58
(0.44–0.77) 0 0.40–0.84 0.49 p > 0.1 Convincing
Ives, et al.
2007 IFN-α + CTx vs CTx Metastatic melanoma 10 662/583
Complete
response OR 0/8/2 <0.001
0.33
(0.19–0.57) 0 0.17–0.64 0.54 p > 0.1 Convincing
Ives, et al.
2017 Adjuvant IFN-α vs obs
High-risk, malignant
melanoma 18 4520/3179 OS HR 0/17/1 0.017
0.91
(0.84–0.98) 0 0.83–0.99 0.22 p > 0.1 Suggestive
Ives, et al.
2017 Adjuvant IFN-α vs obs
High-risk, malignant
melanoma 18 4520/3177
Event-free
survival HR 0/18/0 <0.001
0.86
(0.80–0.92) 0 0.79–0.93 0.23 p > 0.1 Weak
Mocellin, et al.
2013 Adjuvant IFN-α vs CT Metastatic melanoma 15 5412/3771 OS HR 1/10/4 0.004
0.91
(0.85–0.97) 5 0.82–1.00 0.06 p > 0.1 Weak
Mocellin, et al.
2013 Adjuvant IFN-α vs CT Metastatic melanoma 17 5638/3963
Disease-free
survival HR 0/10/7 <0.001
0.82
(0.77–0.88) 13 0.73–0.93 0.03 p > 0.1 Weak
Pirard, et al.
2004 Postsurgical adjuvant IFN-α vs control
Postsurgical Melanoma,
stage IV unincluded 10 1483/1508 Recurrence rate OR 0/7/3 <0.001
0.74
(0.62–0.88) 17 0.53–1.03 0.68 p > 0.1 Suggestive
Wheatley, et
al. 2003 IFN-α vs obs
Metastatic, high-risk
melanoma 14 3144/2037
Recurrence-free
survival HR 0/11/3 <0.001
0.92
(0.88–0.97) 5 0.86–0.99 0.07 NA Weak
Xin, et al.
2016 IFN-α + dacarbazine vs dacarbazine
Cutaneous malignant
melanoma 8 438/357
Overall
response RR 0/6/2 <0.001
1.59
(1.21–2.09) 0 1.13–2.24 0.40 p > 0.1 Suggestive
Xin, et al.
2016 IFN-α + dacarbazine vs dacarbazine
Cutaneous malignant
melanoma 8 438/357
Complete
response RR 0/6/2 <0.001
3.12
(1.75–5.56) 0 1.46–6.66 0.52 p > 0.1 Suggestive
Baldo, et al.
2010
IFN-α maintenance therapy + CT vs CT or
obs Follicular lymphoma 6 686/671 PFS HR 0/3/3 <0.001
0.65
(0.54–0.79) 31 0.42–1.02 0.14 p > 0.1 Suggestive
Rossi, et al.
2010
IFN-α maintenance or consolidation therapy
vs p or obs NSCLC 4 253/235 OS HR 0/3/1 0.016
0.78
(0.64–0.96) 0 0.50–1.22 0.51 p > 0.1 Suggestive
Canil, et al.
2010 IFN-α vs CT
Inoperable RCC,
metastatic or advanced 6 472/475 Mortality HR 0/4/2 0.001
0.79
(0.69–0.91) 4 0.64–0.99 0.65 p > 0.1 Suggestive
Canil, et al.
2010 IFN-α vs CT
Inoperable RCC,
metastatic or advanced 7 493/496 Response OR 0/3/4 <0.001
6.87
(3.29–14.35) 0 2.61–18.05 0.47 p > 0.1 Suggestive
Unverzagt, et
al. 2017
IFN-α monotherapy vs standard targeted
therapy Metastatic RCC 2 582/584 OS HR 1/1/0 0.001
1.28
(1.10–1.49) ‡ 0 - - p > 0.1 Weak
Unverzagt, et
al. 2017
IFN-α monotherapy vs standard targeted
therapy Metastatic RCC 2 582/584 PFS HR 2/0/0 <0.001
2.23
(1.79–2.76) ‡ 0 - - p > 0.1 Weak
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Table 3. Cont.
Author, Year Comparison Cancer Type RCTn.
Intervention
/Control Outcome Metrics R/N/S †
R
p-Value
R SE
(95% CI) I
2(%)
95%
Prediction
Interval
Egger
p-Value
Excess
Significance
Level of
Evidence
Interleukin-2 and others
Roviello, et al.
2017 IL-2 + CTx vs CTx Colorectal cancer 4 153/150
Objective
response RR 0/3/1 0.003
1.65
(1.19–2.28) 0 0.81–3.36 0.60 p > 0.1 Suggestive
Buyse, et al.
2011
IL-2 remission maintenance monotherapy vs
obs Acute myeloid leukemia 6 725/730 OS HR 0/6/0 0.843
1.01
(0.95–1.06) 0 0.93–1.09 0.39 p > 0.1
No
association
Hamm, et al.
2008 IL-2 + IFN-α + CTx vs CTx
Metastatic malignant
melanoma 5 364/365 OS HR 0/5/0 0.642
0.95
(0.78–1.16) 26 0.59–1.55 0.09 NA
No
association
Hamm, et al.
2008 IL-2 + IFN-α + CTx vs CTx
Metastatic malignant
melanoma 6 568/566
Overall
response RR 0/5/1 <0.001
1.52
(1.24–1.87) 0 1.14–2.04 0.19 p > 0.1 Suggestive
Ives, et al.
2007 IL-2 + IFN-α + CTx vs CTx Metastatic melanoma 7 607/599 OS OR 0/7/0 0.729
1.07
(0.74–1.55) 36 0.46–2.50 0.96 p > 0.1
No
association
Ives, et al.
2007 IL-2 + IFN-α + CTx vs CTx Metastatic melanoma 7 527/564
Overall
response OR 0/6/1 <0.001
0.58
(0.44–0.77) 33 0.40–0.84 0.17 p > 0.1 Suggestive
Hotte, et al.
2007 IL-2 based regimen + CTx vs CT or IFN
Unresectable or metastatic
RCC 2 319/100 1-year mortality RR 0/0/2 0.003
0.56
(0.38–0.82) 19 - - p > 0.1 Weak
Rossi, et al.
2010
IFN-γ maintenance or consolidation therapy
vs p or obs Small-cell lung cancer 2 116/111 OS HR 0/2/0 0.538
1.09
(0.82–1.46) 0 - - p > 0.1
No
association
Cancer vaccine
Cao, et al.
2014 DC vs non-DC High-grade glioma 3 44/42 2-year OS OR 0/3/0 0.038
3.41
(1.07–10.81) 0 - - p > 0.1 Weak
Kawalec, et al.
2012 Sipuleucel-T vs p
Castration-resistant
prostate cancer 3 488/249 OS HR 0/1/2 <0.001
0.73
(0.60–0.88) 0 0.22–2.44 0.71 p > 0.1 Suggestive
Ding, et al.
2014
VAX (Tecemotide or EGF vaccine or SRL172
or TG4010 or MAGE-A3 or L-BLP25) vs CTx
or obs or α-tocopherol
NSCLC 6 1363/876 OS OR 0/4/2 0.001 0.56(0.39–0.79) 65 0.34–0.92 0.99 p > 0.1 Weak
Yu, et al. 2017 VAX vs CTx or p Advanced NSCLC 3 1014/595 PFS OR 0/1/2 0.015 1.31(1.05–1.63) 49 0.32–5.33 0.62 p > 0.1 Suggestive
Zhou, et al.
2016
VAX (EGF vaccine or BLP-25 or TG4010, etc)
vs P Advanced NSCLC 5 1314/884 OS HR 0/4/1 0.002
0.83
(0.74–0.93) 17 0.64–1.07 0.20 p > 0.1 Suggestive
Zhou, et al.
2016
VAX (EGF vaccine or BLP-25 or TG4010, etc)
vs CTx Advanced NSCLC 4 300/302 OS HR 0/4/0 0.012
0.77
(0.63–0.94) 0 0.50–1.20 0.55 p > 0.1 Weak
Bai, et al. 2017 Postsurgical AIT (IL-2 + IFN-α or IFN-α2b orIFN-α, etc) vs no AT Locally advanced RCC 5 941/902 OS HR 0/5/0 0.345
1.08
(0.92–1.28) 0 0.83–1.42 0.32 NA
No
association
Abbreviations: RCT, randomized controlled trial; N., number; SE, standard effect; CI, confidence interval; M, model; F, fixed effect; R, random effect; NA, not available; C, concordance with
largest study; Y, concordant with largest study; n, not concordant with largest study; OS, overall survival; PFS progression-free survival; RR, risk ratio; HR, hazard ratio; OR, odds ratio; IFN,
interferon; 5FU, fluorouracil; CTx, chemotherapy; CT, conventional therapy; obs, observation; IL-2, Interleukin-2; DC, dendritic cell based vaccine; p, placebo; VAX, vaccine; EGF, Epidermal
Growth Factor; HCC, hepatocellular carcinoma; NSCLC, non-small cell lung cancer; RCC, renal cell cancer. † Number of individual studies of effect size with statistically significant in
direction in favor of control therapy/not statistically significant/statistically significant in favor of immunotherapy. ‡ The control therapy was favored over the experimental therapy.
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Meta-analyses of adjuvant IFN-α therapy for patients with melanoma included a large number
of participants (>5000). Adjuvant treatment with IFN-α therapy resulted in an improvement in OS,
supported by suggestive evidence, as well as event-free survival, supported by weak evidence because
there was no statistically significant component study. In comparison to controls, the addition of
adjuvant IFN-α decreased the recurrence rate of melanoma after surgical resection. A benefit of
IFN-α on inoperable metastatic RCC as assessed by the mortality and response rate was supported by
suggestive evidence. However, it is worth mentioning that targeted therapy (temsirolimus or sunitinib)
showed a benefit over IFN-α monotherapy in patients with RCC.
With respect to regimens used for the treatment of advanced melanoma, meta-analyses were
performed comparing a combination therapy of cytokines and chemotherapy (“biochemotherapy”)
with chemotherapy alone. IFN-α plus chemotherapy showed a benefit over chemotherapy alone on
the ORR and complete response rate in patients with metastatic melanoma, supported by convincing
evidence. A comparison between IFN-α with dacarbazine and dacarbazine alone also showed an
improvement in the ORR and the complete response rate. The addition of IL-2 and IFN-α to standard
chemotherapy showed no beneficial effect on the survival rate, though it did improve the response rate
in patients with metastatic melanoma (Figure S4).
Adding IL-2 to chemotherapy for the treatment of metastatic colorectal cancer improved the
objective response rate. IL-2 monotherapy did not show clinically meaningful benefit for patients with
acute myeloid leukemia. IL-2 based regimens resulted in a reduction in 1-year mortality in patients
with metastatic RCC. IFN-γ maintenance therapy did not result in a survival benefit in patients with
small-cell lung cancer.
2.4. Cancer Vaccine
The benefit of vaccine therapy in patients with cancers is best supported by suggestive evidence
(Tables 3 and S6, Figure S4). The meta-analysis of trials of Sipuleucel-T showed improved survival
in patients with castration-resistant prostate cancer. DC vaccine therapy showed efficacy in patients
with glioma. Other meta-analyses of the efficacy of cancer vaccines were conducted regardless of the
specific type of cancer vaccines that were used. Meta-analyses showed that cancer vaccines had a
benefit on OS and PFS of patients with NSCLC, compared to a placebo or chemotherapy. No evidence
indicated the benefit of a cancer vaccination on RCC outcome.
3. Discussion
We systematically analyzed all eligible meta-analyses studying the efficacy of cancer
immunotherapy. We assessed 247 meta-analyses by performing re-analysis, including tests for
heterogeneity and various biases, and by classifying each re-analysis according to its level of evidence
determined by applying criteria to the results of re-analysis. Although more than half of the
meta-analyses (142) were statistically significant (p < 0.05) in favor of immunotherapy, only 84 were
classified as suggestive or convincing evidence due to high heterogeneity (28), not containing any
statistically significant studies despite the absence of biases and low heterogeneity (9), implication of
publication bias (26), 95% PI including the null (81), or Egger p-value and 95% PI being unavailable
because analysis was performed on only two component studies (18). Evidence for excess significance
(ES) was found in only one study. Convincing evidence was found in the following nine comparisons:
anti-PD-1/PD-L1 mAb therapy versus chemotherapy on PFS and ORR in patients with advanced
melanoma, anti-PD-1/PD-L1 mAb therapy versus chemotherapy on the OS of patients with NSCLC,
rituximab plus chemotherapy versus chemotherapy on the complete remission rate in patients with
chronic lymphocytic leukemia, rituximab plus chemotherapy versus chemotherapy on the OS and DCR
of patients with B-cell non-Hodgkin’s lymphoma, adoptive cell immunotherapy versus conventional
therapy on 2-year OS of patients with NSCLC, and IFN-α plus chemotherapy versus chemotherapy on
ORR and complete response rate of patients with metastatic melanoma.
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For 25 meta-analyses including non-RCTs in their component study, two types of re-analyses were
performed: (1) with RCTs only and (2) with RCTs and non-RCTs altogether. We reported the former as
the main outcome to minimize the selection bias and effect of possible confounding factors within
trials [14]. While 15 out of 25 re-analyses including only RCTs showed a level of evidence consistent
with their RCT plus non-RCT counterpart, the other 10 showed a change in their level of evidence
(eight being downgraded, two being upgraded). Details are provided in Table S8.
In our study, 195 (79%) meta-analyses showed low or moderate heterogeneity (I2 < 50%) between
individual studies, and 52 (21%) meta-analyses showed large heterogeneity (I2 > 50%). Twenty-six
(11%) meta-analyses showed discrepant results between the fixed and random model, 15 of which had
large heterogeneity between trials. Of 52 meta-analyses with large heterogeneity, 22 were performed
with a fixed model in their original paper. Using a fixed-effects model in high heterogeneity without
fair justification may produce overly precise summary effects whose CI is too narrow, and may give
the wrong impression that common treatment effects exist when there may be a real difference in
the treatment effect between trials [15]. The random-effects model is an appropriate choice for high
between-study heterogeneity since it can account for a genuine difference in treatment effects such as
those caused by differences in study population, differences in the intervention such as different doses,
or differences in follow-up duration.
While the summary effects of random-effects meta-analysis represent the average effect of included
studies, 95% PI estimates the treatment effect of individual studies in future settings [15]. A 95% PI
encompasses the full distribution of effects in a random-effects meta-analysis [16] and further accounts
for between-study heterogeneity in evaluating the uncertainty of expected effects in the future [17],
covering a wider range than CI in the case of high in-between study heterogeneity. 95% PI including
the null value suggests that there may be settings where the intervention effect is null or even in the
opposite direction, and requires further study for the identification of the causes of heterogeneity. 95%
PI excluding the null suggests that the treatment effect is beneficial in at least 95% of the future studies,
and gives the conclusion that the results of treatment effects are fairly consistent, even when significant
between-study heterogeneity is present [15]. It should be noted that out of our 146 re-analyses showing
statistical significance, 95% PI excluded the null in only 43 (29%) of the cases. PI is assessed as
potentially the most relevant and complete statistical inference to be drawn from random-effects
meta-analyses [18] but was not represented in any of the original meta-analyses included in this review.
Future studies need to represent the PI in their meta-analyses of cancer immunotherapy for a better
prediction of the true treatment effect [19].
Egger’s test of funnel plot assumes that the accuracy in estimating the true treatment effect
increases as the sample size of the component studies increases, and assesses a specific type of
heterogeneity compared to the overall test of heterogeneity [20]. The presence of publication bias
may also indicate the presence of reporting bias, selective outcome reporting, and selective analysis
reporting. However, other factors such as genuine heterogeneity or chance may also contribute to
publication bias. A cautious approach is needed when examining publication bias, especially when
between-study heterogeneity is large [21]. Among the original meta-analyses examined in our study,
the Egger p-value was represented in only 18 (7%) of the meta-analyses. In many cases, publication
bias was measured by mere visual examination of the funnel plot or the Egger p-value was calculated
on only some of the outcomes in a study. A thorough examination of Egger p-values is needed when
one assesses publication bias [20].
Precautions should be taken in interpreting the results of our study. First, the type of metrics used
in the analysis should be appreciated. In our study, the odds ratio (OR) was applied in 53 (22%) of
the meta-analyses and RR or HR was applied in the residual 194 (78%). Mistaking OR as RR or HR
may result in unwanted exaggeration of the effect size [22]. Second, one should note that the level of
evidence and effect size represents the efficacy of the intervention relative to the control arm regimen
rather than absolute efficacy of the intervention. For example, while one re-analysis showed that IFN-α
therapy was beneficial on the OS of RCC patients compared to conventional therapy, supported by
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suggestive evidence, another re-analysis showed targeted therapy was more beneficial on the OS of
RCC patients compared to IFN-α therapy, supported by weak evidence (Table 2). When choosing an
optimal therapeutic intervention, all possible treatments should be taken into consideration.
In this review, we have attempted to assess the true efficacy of several cancer immunotherapeutic
approaches, but the study is not without limitations. First, we focused on meta-analyses on the
subject, and therefore individual trials not included in meta-analyses would have been overlooked
in our study. Second, we did not include meta-analyses if they did not provide sufficient individual
study data necessary for re-analysis. Third, although we prioritized RCTs over other studies as the
subject of re-analysis, we did not apply criteria for assessing qualities of individual component RCTs.
Fourth, some statistical limitations exist. ES and 95% PI could not be obtained in the meta-analyses
of two studies, so these meta-analyses were at best classified as weak evidence. There are reports
that the power of Egger’s test for detecting publication bias is too low when there are fewer than
ten studies [21], and the test for ES also typically has low power when there are few studies with a
significant effect [23]. Finally, we did not assess the possible differences in the immunotherapy effects
resulting from different biomarker expression levels. For example, higher PD-L1 expression on the
tumor or immunosuppressive myeloid cells in the tumor microenvironment may correlate with a higher
response rate to anti-PD-1/PD-L1 mAb therapy [10]. In one meta-analysis of anti-PD-1/PD-L1 mAb,
one component trial only accepted patients with tumors having at least 1% of tumor cells positive for
PD-L1, while the other trials accepted patients regardless of PD-L1 expression [24]. Such circumstances
may contribute to significant between-study heterogeneity, which leads to difficulties in interpreting
the potential presence of biases.
4. Materials and Methods
This systematic review was performed according to a pre-specified protocol registered at the
International Prospective Register of Systematic Reviews [25] (registration ID: CRD42018096274).
The reporting was done according to the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines (Table S9) [26].
We identified meta-analyses studying the efficacy of cancer immunotherapy and performed
re-analyses including statistical tests for various biases to evaluate its power of evidence. We also
performed additional meta-analyses of RCTs in cases where no single meta-analysis effectively
covered all trials on a subject, by combining component trials from meta-analyses of interest while
excluding overlapping trials. We set criteria based on our statistical tests and determined how reliable
meta-analyses could be trusted as evidence for assessing the true clinical effect of the treatment.
4.1. Search Strategy and Selection Criteria
Two investigators (JI Shin and JY Kim) independently searched PubMed from inception to 14
February 2018 for any meta-analyses of RCTs that reported efficacy endpoints of cancer immunotherapy.
The search was limited to articles written in English. We used the following search strategy: (randomized
OR randomized controlled trial) AND (meta OR meta-analysis) AND cancer AND (immunotherapy
OR programmed cell death protein OR PD-1 OR PD-L1 OR CD20 OR rituximab OR cytokine-induced
killer cell OR CIK OR dendritic cells co-cultured with cytokine-induced killer cells OR DC/CIK OR
TIL OR Interferon-alpha OR IFN-α OR interleukin-2 OR IL-2 OR cancer vaccine OR dendritic cell).
We then selected eligible articles by first examining the title, then the abstract, and then the full text.
Any discrepancies between the two investigators (JI Shin and JY Kim) were resolved by face-to-face
discussion. A search of the EMBASE database did not result in additional included meta-analyses in
this analysis, as all additional identified articles did not meet the inclusion criteria. They were either
conference publications or did not provide enough data for re-analyses.
Articles were considered eligible if they included meta-analyses conducted with systematic
methods. Meta-analyses conducted on RCTs were deemed eligible. Meta-analyses of observational
studies and retrospective studies were not included. Only meta-analyses containing endpoints
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regarding the efficacy of cancer immunotherapy treatment, such as OS, PFS, ORR, and DCR were
included. Outcomes of individual trials had to be reported in metrics such as HR, RR, or OR.
Articles of meta-analyses on trials of various cancer immunotherapies were included regardless of the
immunotherapy setting, such as induction therapy, maintenance/salvage therapy, and pre/postsurgical
adjuvant therapy. Articles where immunotherapy trials were included in a subgroup of meta-analyses
were also included. When all component studies of a meta-analysis were included in another
meta-analysis, the smaller meta-analysis was excluded when the results of both were comparable.
From eligible articles, we extracted the title, first author, and year of publication. For each
meta-analysis, we extracted the following: intervention therapy, control therapy, cancer of interest,
number of patients, number of studies, outcome of interest, type of outcome metrics, analysis model,
effect size and 95% CI of each RCT, summary effect size, p-value, I2 for evaluation of heterogeneity, and
Egger p-value.
4.2. Data Analysis
From each article, we calculated the summary effect size and its 95% CI and p-Value with both
fixed and random-effects models. The effect size under a random-effects model was assessed for
determining the level of evidence. Results were obtained with identical type of metrics as in the original
analyses, and were calculated from the raw data of individual component trials. All reported p-Values
were two-sided. Analyses used Comprehensive Meta-Analysis v3.3.070 and Microsoft Excel v16.0.
We performed a Q-test for the evaluation of heterogeneity and calculated the I2 metrics [27].
I2 ranged between 0% and 100% and described the percentage of variability in a study estimate that was
due to between-study heterogeneity. An I2 value below 50% represented low or moderate heterogeneity
while a value above 50% represented large heterogeneity [28]. The 95% PI, which estimates the range
where a true effect of the intervention is to be expected for 95% of similar studies in the future [18],
was also estimated for further exploration. PIs including the null value suggested that the measured
effect might not be reproducible in future trials. Conversely, a PI of 95% excluding the null suggested
that the effect would persist in at least 95% of the future studies, and therefore we concluded that the
effect of the intervention was consistent.
We also assessed whether the summary outcome of a random-effects meta-analysis and outcome
of its largest component study showed concordance in terms of statistical significance (p < 0.05).
We also assessed the presence of publication bias, measured by a regression asymmetry test proposed
by Egger et al. [20]. Publication bias was claimed at Egger p-Value < 0.10.
We performed a test for ES to evaluate whether the number of studies reporting nominally
significant results (p < 0.05) was greater compared to the expected number of studies reporting
statistically significant results [29]. The expected number of statistically significant studies was
calculated as the sum of the power of individual component studies [23]. In two cases where the
power of all individual studies was not available (Vidal et al. 2017, Rituximab maintenance versus
observation or treatment only at relapse, follicular lymphoma; and Mocellin et al. 2013, adjuvant IFN-α
versus conventional therapy, metastatic melanoma; see Tables 1 and 2), we assumed that the power of
each study could be replaced by the power of the study with the largest number of participants [30].
The power of individual studies was estimated in terms of non-central t distribution, with the aid of
G*Power ver. 3.0.10 [31]. Statistic A was calculated in terms of χ2 distribution, and ES was claimed at
p < 0.1 with the number of observed statistically significant studies larger than the expected number of
significant studies [23]. The presence of ES under low or moderate heterogeneity (I2 < 50%) suggested
that the meta-analysis was affected by some kind of bias, such as publication bias, selective analysis, or
outcome reporting bias [30]. It is worth noting that we performed post-hoc power analysis to assess
excess significance bias within the meta-analyses, rather than to distinguish between the true negative
effects and false-negative effects in negative associations, which is a controversial statistical method
that may provide misleading information.
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If an original meta-analysis was based on one or more non-RCT(s), re-analysis was conducted on
both conditions: (1) with RCTs only and (2) with all component studies including non-RCT(s), although
the former was reported as the main outcome. We also obtained the quality of the individual studies in
the eligible meta-analyses using the Cochrane risk of bias tool. Its results are reported in Table S10.
We applied the following criteria for each meta-analysis to determine the strength of its evidence
as a proof of the efficacy of immunotherapy compared to control therapy. The respective algorithm is
shown in Figure S8.
Weak evidence: statistically significant result (random-effects p-Value < 0.05)
Suggestive evidence: (1) statistically significant result (random-effects p-Value < 0.05), (2) low or
moderate heterogeneity (I2 < 50), (3) no evidence of publication bias (Egger p-Value > 0.1), and (4) no
evidence of ES (ES p-Value > 0.1)
Convincing evidence: (1) highly statistically significant result (random-effects p-Value < 0.001),
(2) low or moderate heterogeneity (I2 < 50), (3) no evidence of publication bias (Egger p-Value > 0.1),
(4) no evidence of ES (ES p-Value > 0.1), (5) 1,000 or more participants, (6) summary outcome shows
concordant result with the largest study, and (7) 95% PI excludes the null hypothesis.
When a meta-analysis had no evidence of publication bias or ES but had high in-between study
heterogeneity (I2 > 50), we rechecked the results of its component studies to find out whether the high
heterogeneity was due to the differences in the direction of effects or due to the differences in the size
of the associations. When the number of statistically significant component studies was the same or
greater than the number of studies, which were not significant or significant in the opposite direction,
the comparison was classified as suggestive evidence, or as convincing evidence if further criteria
were also met. When no statistically significant component study was observed in a meta-analysis,
the analysis was at best classified as weak evidence.
5. Conclusions
We comprehensively re-analyzed meta-analyses of various cancer immunotherapeutic approaches
by assessing the presence of various potential biases affecting the efficacy of immunotherapy compared
to control therapy, and determined how reliable the analysis could be trusted by defining the level
of evidence for each comparison. Even though more than half of the 247 meta-analyses reporting on
the efficacy of immunotherapy showed statistically significant results, only nine provided convincing
evidence while 75 highlighted suggestive evidence. One cannot state that treatments supported by
a low level of evidence are not effective, but there is still some uncertainty in them that should be
resolved. Further studies with accurate assessment of potential biases and appropriate interpretation
of heterogeneity are needed to confirm the true effect of cancer immunotherapy.
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